No Data
No Data
GRI Bio Reports Q2 Results
GRI Bio | 10-Q: Q2 2024 Earnings Report
GRI Bio Shares Informational Update Not for Legal Use
GRI Bio Believes That Its Existing Cash and Cash Equivalents Will Be Sufficient to Fund Its Operating Expenses and Cap Expenditure Requirements Into the 1Q of 2025 >GRI
Express News | GRI Bio Inc - GRI-0621 Interim Data Readout of Phase 2a Biomarker Study on Track for Q4 2024 and Topline Data on Track for Q1 2025
GRI Bio Had Cash and Cash Equivalents of $6.4M at June 30 >GRI
No Data